About this file

This is a Statement of Objectives (SOO) for a Defense Advanced Research Projects Agency (DARPA) solicitation CBD254-002, focused on developing forward-deployed production capabilities for sterile saline solutions and water for injection to support soldier healthcare.

The objective is to establish a far-forward capability for producing sterile saline and sterile water for injection solutions that can be deployed with military forces. The requirement addresses critical vulnerabilities in the U.S. pharmaceutical supply chain, exemplified by recent shortages caused by hurricane damage to manufacturing facilities in North Carolina. The solutions are essential for wound cleansing, chemical warfare agent decontamination, intravenous rehydration, medication dilution, and inhalation therapy. By enabling production at forward locations using portable equipment, the government seeks to reduce reliance on CONUS shipping of heavy, water-based products (1 kilogram per liter) and mitigate supply chain risks during large-scale military operations.

The effort is structured in three phases: Phase I requires demonstration of proof-of-concept production of sterile saline and water using nonsterile source water under Current Good Manufacturing Practice (CGMP) regulations, with equipment fitting within two CONEX containers (20 feet wide, 40 feet long). Applicants must implement Quality by Design methodology, provide Certificates of Analysis demonstrating compliance with USP and FDA standards, and present a plan for Phase II engineering runs. Phase II involves finalizing equipment, processes, and automation to enable fill-finish production of IV-bagged solutions meeting USP criteria, with successful completion supporting Abbreviated New Drug Application (ANDA) and Drug Master File (DMF) submissions to the FDA. Direct-to-Phase II applicants with third-party funding are eligible. Phase III focuses on demonstrating field-portable, at-scale production meeting FDA CGMP standards for civilian and military emergency response applications. No CMMC requirement applies, and no technical point of contact is provided.

View the file

Other files

File Type Posted
CBD_SBIR_254_R4.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

CBD254-002: Production of Saline Solutions and Sterile Water Forward Deployed for Soldier Health Care

PROJECTED CMMC LEVEL REQUIREMENT:

N/A

TECHNOLOGY AREAS:

Chem Bio Defense

MODERNIZATION PRIORITIES:

Biotechnology

KEYWORDS:

sterile solutions; intravenous solutions; water for injection; water for irrigation; ANDA;CGMP; COA; Quality By Desig; pharmaceutical production

ADDITIONAL INFORMATION

N/A

OBJECTIVE:

Provide a far-forward capability for producing sterile saline and water for injection solutions for soldier healthcare.

DESCRIPTION:

The Department of Defense requires vast quantities of sterile saline and sterile water for injection for treatment of wounded soldiers. Sterile saline and water are both commonly used for wound cleansing, particularly for soldiers encountering mustard or blistering chemical warfare agents. Sterile saline for intravenous use is the most commonly used crystalloid rehydration solution used in patient care. Sterile water for injection is also used for medication dilution to reconstitute powdered medications or dilute concentrated solutions, inhalation therapy to humidify air or deliver medications via nebulizers, and laboratory use to prepare samples and reagents.

The current shortage in IV saline across the entire US was due to flooding in 1 factory in North Carolina affected by Hurricane Helene. This shortage affected every health care facility in the country; if such a shortage occurred during large scale military operations, it would have an adverse effect on military health care.

Sterile saline and water weigh 1 KG (2.2 lbs) for each 1 liter bag; shipping all of these bags to remote locations consumes large quantities of resources that could be repurposed to other warfighting uses if these solutions could be prepared forward deployed rather than in CONUS. Providing alternate locations for production mitigates DOD’s risk for supply chain management and decreases resources required for shipment of critical pharmaceutical products.

Successful applicants will be chosen based on the soundness of the proposal, demonstrated pharmaceutical production experience, and deep knowledge of pharmaceutical manufacturing.

PHASE I:

Demonstrate proof of concept production of drug substance sterile saline and sterile water produced using nonsterile source water made under Current Good Manufacturing Practice (CGMP) regulations using equipment that can be packaged in no more than 2 CONEX containers (20 ft wide, 40 ft long). Devise and implement a Quality By Design approach for production consistent with FDA guidelines implementing robust metrology, in-line process analytical testing, automation and informatics. Certificates of Analysis (COAs) should be provided for proof of concept runs to demonstrate successful compliance with applicable USP and FDA standards. Successful Phase 1 performers will show product production and a clear plan to achieve success for engineering runs required in Phase II.

PHASE II:

Finalize equipment package and processes (critical process parameters, process automation, real-time monitoring, informatics, quality systems) necessary for fill finish production of sterile saline and water for injection packaged in IV bags. Sterile saline and water for injection packaged in IV bags must meet USP criteria for production. Demonstrate production of sterile saline and water for injection in IV bags in engineering runs to support an Abbreviated New Drug Application for the Food and Drug Administration. A successful Phase II performer will show actual production of sterile IV saline and water for injection under CGMP with acquired data to support a Drug Master File (DMF) and an Abbreviated New Drug Application (ANDA) submission.

Direct to Phase II: Eligible Phase II applicants may also apply directly to Phase II awards with support from third-party investors or strategic partners and USG matched funds. This program is well positioned as an inject to the MCM MFRO (Medical Countermeasures Manufacturing Optimization) program in JPEO for follow-on funding and work. Phase II performers will be chosen based on results achieved in Phase II. The expected outcome is an ANDA submission to the FDA for production of sterile IV saline and water for injection.

PHASE III DUAL USE APPLICATIONS:

Development of a field-portable method of making IV saline solutions and water for injection would be a very useful tool in the aftermath of a national emergency or in the aftermath of a national shortage due to damage to US based manufacturing. The recent damage to the Baxter Healthcare plant in North Carolina after Hurricane Helene shows how vulnerable the US is to supply chain risks associated with these essential pharmaceutical products. The needs of the US military are focused on producing needed sterile solutions far forward to minimize shipment of water solutions from the US and to provide redundancy in case of factory failures in the US. A Phase III performer will demonstrate at scale production of sterile IV saline and water for injection that meets FDA standards of CGMP production.

REFERENCES:

Not provided by topic author.1.

TECHNICAL POINT OF CONTACT (TPOC):

None

File details come from the government source that posted it. Updated .